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Abstract
The nonrandomized phase 2 APEC trial investigated ﬁrst-line once-every-2-weeks cetuximab plus chemo-
therapy (investigator’s choice of FOLFOX or FOLFIRI) studied patients with KRAS/RAS wild-type metastatic
colorectal cancer. We observed an activity and safety proﬁle similar to that reported in prior ﬁrst-line pivotal
studies involving weekly cetuximab, suggesting that once-every-2-weeks cetuximab is effective and tolerable
as ﬁrst-line therapy.
Background: In patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC), outcomes with ﬁrst-line
chemotherapies are improved by adding weekly cetuximab. The APEC study investigated ﬁrst-line once-every-2-
weeks cetuximab plus chemotherapy for patients with KRAS wt mCRC; additional biomarker subgroups were also
analyzed. Patients and Methods: APEC was a nonrandomized phase 2 trial conducted in the Asia-Paciﬁc region.
Patients (n ¼ 289) received once-every-2-weeks cetuximab with investigator’s choice of chemotherapy (FOLFOX or
FOLFIRI). The primary end point was best conﬁrmed overall response rate (BORR); progression-free survival (PFS) andCurrently associated with Gleneagles Penang, Penang, Malaysia.
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Once-Every-2-Weeks Cetuximaboverall survival (OS) were secondary end points. Early tumor shrinkage (ETS) and depth of response (DpR) were also
evaluated. Results: In the KRAS wt population, BORR was 58.8%, median PFS 11.1 months, and median OS
26.8 months. Expanded RAS mutational analysis revealed that patients with RAS wt mCRC had better outcomes
(BORR ¼ 64.7%; median PFS ¼ 13.0 months; median OS¼ 28.4 months). The data suggest that ETS and DpR may be
associated with survival outcomes in the RAS wt population. Although this study was not designed to formally assess
differences in outcome between treatment subgroups, efﬁcacy results appeared similar for patients treated with
FOLFOX and FOLFIRI. There were no new safety ﬁndings; in particular, grade 3/4 skin reactions were within clinical
expectations. Conclusion: The observed activity and safety proﬁle is similar to that reported in prior ﬁrst-line pivotal
studies involving weekly cetuximab, suggesting once-every-2-weeks cetuximab is effective and tolerable as ﬁrst-line
therapy and may represent an alternative to weekly administration.
Clinical Colorectal Cancer, Vol. -, No. -, 1-11 ª 2016 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The antieepidermal growth factor receptor (EGFR) monoclonal
antibody cetuximab has been approved for the ﬁrst-line treatment of
patients with RAS wild-type (wt) metastatic colorectal cancer
(mCRC). The addition of weekly cetuximab at a dose of 250 mg/m2
(after an initial dose of 400mg/m2) to standard ﬁrst-line infusional 5-
ﬂuorouracil (5-FU)-based chemotherapy regimens including oxali-
platin (FOLFOX [oxaliplatin, folinic acid, 5-FU]) or irinotecan
(FOLFIRI [5-FU, folinic acid, irinotecan]) improves clinical outcome
in patients with KRAS wt or RAS wt mCRC, as demonstrated in the
randomized OPUS and CRYSTAL studies, respectively.1-5
Cetuximab has a mean half-life of 112 hours, and pharmacokinetic
data suggest similar steady-state bioavailability for the standard weekly
schedule of cetuximab (250mg/m2) and a once-every-2-weeks dose of
500 mg/m2.6 It is therefore plausible that cetuximab could be
administered according to a once-every-2-weeks dosing schedule.
Recent clinical evidence supports the activity and tolerability of such a
regimen at a dose of 500 mg/m2.7-10 Such a dosing schedule would
potentially be more convenient to patients, particularly due to the 2-
week dosing cycles utilized for FOLFOX and FOLFIRI.
In light of these prior observations, a multicenter, nonrandomized
phase 2 APEC study was conducted to assess the efﬁcacy and safety of
500mg/m2 cetuximab once-every-2-weeks combined with FOLFOX
or FOLFIRI as ﬁrst-line treatment for patients withKRASwtmCRC.
To reﬂect the outcome in the population for which cetuximab is
currently approved, we also performed exploratory subgroup analyses
based on expanded RAS mutational status (KRAS and NRAS
exons 2-4). Further analyses considered BRAF and PIK3CA muta-
tional testing, EGFR expression status, and the potential association
between early tumor shrinkage (ETS) and depth of response (DpR)
with survival outcomes. Because FOLFOX and FOLFIRI have shown
similar efﬁcacy in patients with mCRC,11 including when used in
combination with cetuximab,12,13 the study design included a non-
randomized allocation to either chemotherapy regimen, based on
investigator’s choice.
Patients and Methods
Study Design and Patients
APEC (NCT00778830) was a multicenter, nonrandomized,
open-label phase 2 exploratory trial carried out in the Asia-Paciﬁcnical Colorectal Cancer Month 2016region. APEC included adult patients (aged  18 years) from the
Asia-Paciﬁc region with KRAS wt metastatic adenocarcinoma of the
colon or rectum. KRAS wt was deﬁned as no detected mutations in
KRAS exon 2 (codon 12/13). Eligible patients were required to have
a life expectancy of  12 weeks, an Eastern Cooperative Oncology
Group performance status of 0 or 1, presence of  1 bidimen-
sionally measurable index lesion, and written informed consent.
Patients were excluded if they had known or suspected brain
metastasis and/or leptomeningeal disease; previous treatment with
chemotherapy for colorectal cancer (excluding adjuvant therapy
terminated > 6 months previously); or radiotherapy, surgery
(excluding prior diagnostic biopsy), or any investigational drug in
the 30 days before the start of treatment in this study.
All patients received cetuximab (500 mg/m2) on the ﬁrst day
of every 14-day treatment cycle over 120 minutes for the ﬁrst
infusion, 90 minutes at the second infusion, and 60 minutes at the
subsequent infusions. According to investigator’s choice, patients
received either FOLFOX (oxaliplatin 100 mg/m2, folinic acid
(FA) 200 mg/m2 L-form or 400 mg/m2 racemic, then 5-FU as a
400 mg/m2 intravenous bolus and a 2400 mg/m2 continuous
infusion over 46 hours) or FOLFIRI (irinotecan 180 mg/m2,
FA 200 mg/m2 L-form or 400 mg/m2 racemic, then 5-FU as a
400 mg/m2 intravenous bolus and a 2400 mg/m2 continuous
infusion over 46 hours) (Figure 1). Treatment was planned to
continue until the disease progressed, unacceptable toxicity was
reported, or consent was withdrawn; when chemotherapy was dis-
continued, continuation of cetuximab as a maintenance regimen
(until disease progression) was to be considered. After the end of
study treatment, information on further anticancer treatment and
survival was collected every 3 months.
Outcomes
Because all patients in the intention-to-treat (ITT) population
received  1 dose of study treatment, efﬁcacy analyses and safety
assessments were conducted on the ITT population, which was
deﬁned as all patients with KRAS wt mCRC who received  1 dose
of either study treatment (n ¼ 289). The primary end point was the
best overall conﬁrmed response rate (BORR); response to treatment
was assessed every 8 weeks by radiologic imaging according to
Response Evaluation Criteria In Solid Tumors (RECIST) 1.0.
Figure 1 APEC Study Proﬁle. *Includes Patients With KRAS Exon 3/4 Mutations, NRAS Exon 2/3/4 Mutations, and New KRAS Exon 2
Mutations Identiﬁed by NGS
Abbreviations: FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; ITT ¼ intention-to-treat; mt ¼ mutant; NGS ¼ next-generation sequencing; wt ¼ wild type.
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Ann-Lii Cheng et alSecondary end points were progression-free survival (PFS), overall
survival (OS), and safety. In assessing the potential relationship of
documented adverse events (AEs) to the study drugs (ie, cetuximab
and/or chemotherapy), it was assumed that the AE was related to
the study drugs unless the investigator deﬁnitively reported that the
AE was unrelated to the study drugs.
The number of patients who underwent metastatic surgery,
together with information on the localization of metastases removed
and outcome of surgery with respect to residual tumor after surgery
(R0, R1, R2, not evaluable), was evaluated in an exploratory anal-
ysis. In case of resection of > 1 metastasis, the worst outcome of
surgery deﬁned overall status.
All patients with an available tumor size evaluation at baseline
and week 8 (n ¼ 269) were considered for an exploratory analysis of
the potential association between ETS and survival outcomes (PFS
and OS). ETS was categorized as  20% decrease in the sum of
longest diameters of target lesions between baseline and posttreat-
ment week 8.
A total of 159 patients with RAS wt mCRC were considered
evaluable for an exploratory analysis of DpR, including its potential
association with efﬁcacy outcomes (PFS as well as OS). Evaluable
patients were those who had quantitative tumor size assessmentsavailable from baseline and at least 1 postbaseline visit. DpR was
deﬁned as the extent of maximal tumor shrinkage (sum of tumor
diameters at nadir divided by sum of tumor diameters at baseline)
and was expressed as a percentage. Assessments were performed
every 8 weeks by computed tomography or magnetic resonance
imaging according to RECIST 1.0.
Expanded RAS Testing and Exploratory Biomarker
Analysis
Expanded RAS (KRAS and NRAS exons 2-4; including retesting
of KRAS exon 2) mutational status was assessed by Ion Torrent (Life
Technologies, Thermo Fisher Scientiﬁc Life Sciences, Waltham,
MA) next-generation sequencing (NGS). RAS wt was deﬁned as no
mutations in KRAS and NRAS exons 2-4; RAS mutant (mt) was
deﬁned as  1 mutation in exons 2-4 of KRAS and/or NRAS. Upon
retesting via NGS, KRAS exon 2 mutations were detected in 10
patients from the KRAS wt ITT population, potentially owing to
the higher sensitivity of NGS compared with the direct sequencing
method initially used to screen patients for eligibility. These 10
patients were included, along with patients with KRAS exon 3-4 and
NRAS exon 2-4 mutations, in the RAS mt population during the
exploratory analysis.Clinical Colorectal Cancer Month 2016 - 3
Table 1 Baseline Demographics in KRAS wt and RAS wt Populations
Characteristic
KRAS wt (ITT) Population, n (%) RAS wt Populationn (%)
Total
(n [ 289)
Cetuximab D
FOLFOX (n [ 188)
Cetuximab D
FOLFIRI (n [ 101)
Total
(n [ 167)
Cetuximab D
FOLFOX (n [ 110)
Cetuximab D
FOLFIRI (n [ 57)
Sex
Male 185 (64.0) 119 (63.3) 66 (65.3) 108 (64.7) 72 (65.5) 36 (63.2)
Female 104 (36.0) 69 (36.7) 35 (34.7) 59 (35.3) 38 (34.5) 21 (36.8)
Age, years
<65 215 (74.4) 145 (77.1) 70 (69.3) 131 (78.4) 88 (80.0) 43 (75.4)
65 74 (25.6) 43 (22.9) 31 (30.7) 36 (21.6) 22 (20.0) 14 (24.6)
Region
East Asia 167 (57.8) 94 (50.0) 73 (72.3) 86 (51.5) 46 (41.8) 40 (70.2)
Australia 29 (10.0) 21 (11.2) 8 (7.9) 25 (15.0) 17 (15.5) 8 (14.0)
South Asia 31 (10.7) 19 (10.1) 12 (11.9) 15 (9.0) 10 (9.1) 5 (8.8)
Southeast Asia 62 (21.5) 54 (28.7) 8 (7.9) 41 (24.6) 37 (33.6) 4 (7.0)
Ethnic origin
Asian 259 (89.6) 167 (88.8) 92 (91.1) 141 (84.4) 92 (83.6) 49 (86.0)
Caucasian 29 (10.0) 21 (11.2) 8 (7.9) 26 (15.6) 18 (16.4) 8 (14.0)
Other 1 (0.3) 0 1 (1.0) 0 0 0
Leukocytes
10,000/mm3 233 (80.6) 146 (77.7) 87 (86.1) 136 (81.4) 85 (77.3) 51 (89.5)
>10,000/mm3 39 (13.5) 31 (16.5) 8 (7.9) 22 (13.2) 18 (16.4) 4 (7.0)
Missing 17 (5.9) 11 (5.9) 6 (5.9) 9 (5.4) 7 (6.4) 2 (3.5)
Primary tumor site
Colon 157 (54.3) 106 (56.4) 51 (50.5) 96 (57.5) 68 (61.8) 28 (49.1)
Rectum 117 (40.5) 72 (38.3) 45 (44.6) 59 (35.3) 34 (30.9) 25 (43.9)
Colon þ rectum 15 (5.2) 10 (5.3) 5 (5.0) 12 (7.2) 8 (7.3) 4 (7.0)
Metastatic site
Liver only 85 (29.4) 55 (29.3) 30 (29.7) 54 (32.3) 33 (30.0) 21 (36.8)
Other metastasis 203 (70.2) 133 (70.7) 70 (69.3) 112 (67.1) 77 (70.0) 35 (61.4)
No metastases 1 (0.3) 0 1 (1.0) 1 (0.6) 0 1 (1.8)
Prior therapy
Adjuvant 87 (30.1) 40 (21.3) 47 (46.5) 10 (6.0) 5 (4.5) 5 (8.8)
Neoadjuvant 14 (4.8) 9 (4.8) 5 (5.0) 1 (0.6) 1 (0.9) 0
Abbreviations: FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; wt ¼ wild type.
Once-Every-2-Weeks Cetuximab
4 - CliMutational status of BRAF and PIK3CA was assessed retrospec-
tively by pyrosequencing. EGFR expression was assessed by
immunohistochemistry using an EGFR pharmDx Kit (Dako,
Glostrup, Denmark; Agilent Technologies, Santa Clara, CA) with a
cutoff point of  5% of tumor cells exhibiting a staining intensity
of  1þ for deﬁning EGFR-detectable (< 5% was deﬁned as
EGFR-undectable).
Statistical Analysis
The primary analysis was planned to be performed in the ITT
KRAS wt population. The study design did not plan for direct or
statistical comparison between the FOLFOX and FOLFIRI treat-
ment subgroups, as this comparison was not supported by
randomization. The response rate from the overall population, as
well as each treatment subgroup, and its 95% conﬁdence interval
(CI) was calculated using the Clopper-Pearson method. Estimates
for the secondary efﬁcacy variables PFS and OS were describednical Colorectal Cancer Month 2016applying the Kaplan-Meier method. All analyses were performed
using SAS 9.1 or later software (SAS Institute, Cary, NC).
The sample size determination was not based on power consid-
erations for a statistical test but on the conﬁdence limit approach to
ensure adequate precision of estimates. Based on the results from the
CRYSTAL and OPUS studies,1,2,4,5 a precision of estimates with
55% as the expected BORR in each of the 2 treatment subgroups
was selected. A length of the 2-sided 95% CI (not exceeding 10
percentage points in each direction from the point estimate) was
used as a reasonable precise estimate of the BORR for each of the 2
treatment subgroups if  96 patients received that speciﬁc combi-
nation treatment.
Results
Patient Populations
The ﬁrst patient entered our study in February 2009, and the last
patient’s ﬁnal treatment visit was in April 2014. In total, 289
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Ann-Lii Cheng et alpatients comprised the ITT (KRAS wt) population. The 5 countries
with the highest participation were China (21.1%), Taiwan
(15.9%), South Korea (13.1%), Australia (10.0%), and India
(8.0%). In the KRAS wt population, 188 patients (65.1%) were
treated with cetuximab plus FOLFOX, and 101 patients (34.9%)
received cetuximab plus FOLFIRI.
Additional biomarker testing within the KRAS wt ITT population
was conducted to assess the potential inﬂuences of mutations in RAS
(KRAS andNRAS exons 2-4). Among the tumors from 203 evaluable
patients, 167 (82.3%) were found to be RAS wt, deﬁned as having no
detectable mutations in exons 2-4 of KRAS and NRAS. The fre-
quencies of BRAF and PIK3CAmutations were low (5.5% for BRAF;
3.5% and 1.0% for PIK3CA exons 9 and 20, respectively)
(Supplemental Table 1; available in the online version). Due to the
small number of patients with BRAF and PIK3CA mutations, the
BRAF/PIK3CAmt groups were combined in our subsequent analyses.
Within the KRAS wt population, the baseline characteristics of
the 2 treatment subgroups were generally well balanced. However,
several exceptions existed, including the percentage of patients who
were aged  65 years (22.9% FOLFOX and 30.7% FOLFIRI),
baseline leukocyte count > 10,000/mm3 (16.5% FOFOX and
7.9% FOLFIRI), and prior adjuvant therapy (21.3% FOLFOX and
46.5% FOLFIRI; previous oxaliplatin exposure in the adjuvant
setting may have contributed to an increased frequency of in-
vestigator’s choice of FOLFIRI in this study). Baseline characteris-
tics of the RAS wt population were broadly similar to those of the
KRAS wt population (Table 1).
Exposure to cetuximab and chemotherapy (irinotecan or oxali-
platin plus 5-FU), as measured by relative dose intensity, was similar
between the 2 treatment subgroups (Supplemental Table 2; avail-
able in the online version). Furthermore, cetuximab relative dose
intensity was  80% in the majority of patients in the KRAS wt,
RAS wt, RAS mt, and RAS-evaluable populations (> 70% of pa-
tients in each population), with no major differences between the
populations (data not shown). The median duration of cetuximab
treatment was relatively long (z7.5 months; 32.1 weeks in the
FOLFOX subgroup and 33.3 weeks in the FOLFIRI subgroup) and
exceeded the median duration of chemotherapy administration
(25.4 weeks for oxaliplatin; 32.0 weeks for irinotecan; and 27.8
weeks and 32.0 weeks for 5-FU in the FOLFOX and FOLFIRI
subgroups, respectively), suggesting that investigators followed the
recommendation to use cetuximab as maintenance therapy after
withdrawal of chemotherapy (Supplemental Table 3; available in the
online version).
Efﬁcacy
Key efﬁcacy measures for both the KRAS wt and RAS wt pop-
ulations are summarized in Table 2. The KRAS wt and RAS-
evaluable populations were comparable.
In the KRAS wt population, BORR, the primary end point of the
study, was 58.8% (95% CI, 52.9-64.6); further reﬁnement of the
most appropriate patient pool via expanded RAS analysis revealed a
BORR of 64.7% (95% CI, 56.9-71.9) in the RAS wt population.
Consistent with the relatively long median duration of treatment,
median PFS was 11.1 months (95% CI, 9.3-11.8) and 13.0 months
(95% CI, 11.1-14.8) in the KRAS wt and RAS wt populations,
respectively. Median OS in the KRAS wt population was 26.8Clinical Colorectal Cancer Month 2016 - 5
Figure 2 Progression-Free Survival (A, B) and Overall Survival (C, D) According to Treatment Subgroup in KRAS wt (A, C) and RAS wt
(B, D) Populations
A
B
Abbreviations: FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; OS ¼ overall survival; PFS ¼ progression-free survival; wt ¼ wild type.
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6 - Climonths (95% CI, 23.4-29.7); in the RAS wt population, median
OS was further improved (28.4 months [95% CI, 24.4-32.3])
(Table 2 and Figure 2). The survival rate in the KRAS wt population
was 33% at 36 months and 23% at 48 months (36% and 26%,
respectively, in the RAS wt population).
As anticipated, BORR, median PFS, and median OS were rela-
tively low in patients with RAS mt mCRC, as compared with pa-
tients with RAS wt mCRC (Table 2).
The study was not designed to assess differences in outcomes
based on treatment subgroup. However, as expected, efﬁcacy results
were similar for patients treated with FOLFOX versus FOLFIRI in
both the KRAS wt and RAS wt populations (Table 2 and Figure 2).
Posteﬁrst-line anticancer treatment was received by 59.2% of
the KRAS wt population. The most common posteﬁrst-line treat-
ment administered was chemotherapy (52.2%), and relatively fewnical Colorectal Cancer Month 2016patients ( 20.8%) received posteﬁrst-line biologics (Supplemental
Table 4; available in the online version).
We also sought to address efﬁcacy within a biomarker subpop-
ulation deﬁned by BRAF and PIK3CA mutational status. Among
203 evaluable patients, 175 were wt at both BRAF and PIK3CA, 15
with BRAF mt and PIK3CA wt, 12 were BRAF wt and PIK3CA mt,
and 1 was BRAF mt and PIK3CA mt. BRAF/PIK3CA wt patients
appeared to have numerically improved outcomes compared with
patients with BRAF mt and/or PIK3CA mt tumors; however,
deﬁnitive conclusions were precluded by the limited number of
patients with BRAF/PIK3CA mutations in our study (Supplemental
Table 5; available in the online version).
Additional biomarker efﬁcacy subanalyses were conducted on
the basis of EGFR expression. Among 154 evaluable patients, 124
had detectable EGFR expression versus 30 with undetectable
Figure 2 continued
C
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Ann-Lii Cheng et alEGFR expression. There were no major differences in outcome
between the EGFR subgroups, although caution is required when
interpreting these analyses due to the small number of patients in
some subgroups (Supplemental Table 6; available in the online
version).
During the study, 31 patients (10.7%) underwent surgery with
curative intent (24 [12.8%] in the FOLFOX subgroup and 7
[6.9%] in the FOLFIRI subgroup). The R0 resection rate was
10.0% (29 of 289) in the KRAS wt population (22 [11.7%] in the
FOLFOX subgroup and 7 [6.9%] in the FOLFIRI subgroup).
Palliative surgery was undertaken in 5 additional patients (1 in the
FOLFOX subgroup and 4 in the FOLFIRI subgroup). Thus, a total
of 36 patients in the KRAS wt population underwent on-study
surgery for metastases. The R0 resection rate was 10.8% (18 of
167) within the RAS wt population (15 [13.6%] in the FOLFOX
subgroup and 3 [5.3%] in the FOLFIRI subgroup), and a total of
23 patients (13.8%) underwent on-study surgery for metastases.Assessment for ETS was evaluable in 269 and 159 patients in the
KRAS wt and RAS wt populations, respectively. Overall, 76.2%
(205 of 269) of the evaluable patients with KRAS wt mCRC ach-
ieved ETS, whereas ETS occurred in 81.8% (130 of 159) of
evaluable patients with RAS wt mCRC. In patients with KRAS wt
and RAS wt mCRC, ETS was associated with longer PFS and OS;
there were no major differences between the FOLFOX and FOL-
FIRI subgroups (Table 3).
The extent of tumor shrinkage was similar between the FOL-
FOX and FOLFIRI treatment subgroups; among patients whose
disease did not progress, tumor size continued to decrease as the
duration of treatment increased (Supplemental Figure 1; available
in the online version). 159 patients with RAS-wt mCRC were
evaluable for DpR: median DpR was 62.2% (interquartile range
[IQR], 39.1-80.0) within the overall DpR-evaluable population;
within the FOLFOX (n ¼ 103) and FOLFIRI (n ¼ 56) treatment
subgroups, median DpR was 62.2% (IQR, 40.0-80.7) and 62.5%Clinical Colorectal Cancer Month 2016 - 7
Table 3 Association of PFS and OS With Early Tumor Shrinkage in KRAS wt and RAS wt Populations
Population
Total Cetuximab D FOLFOX Cetuximab D FOLFIRI
ETS (‡20%) ETS (<20%) ETS (‡20%) ETS (<20%) ETS (‡20%) ETS (<20%)
KRAS wt (ITT)
n 205 64 134 38 71 26
Median OS (95% CI), months 30.1 (27.2-33.8) 16.4 (11.1-21.5) 29.1 (25.7-32.8) 16.9 (8.8-22.8) 31.7 (26.3-40.5) 15 (9.6-18.7)
Median PFS (95% CI), months 12.7 (11.1-14.2) 5.5 (3.6-7.4) 11.8 (11.1-14.2) 6.3 (3.6-7.7) 12.7 (10.3-15.2) 4.1 (2.4-5.9)
RAS wt
n 130 29 83 20 47 9
Median OS (95% CI), months 30.3 (26.3-33.2) 16.4 (10.3-31.2) 29.7 (24.5-32.8) 16.9 (8.2-37.2) 31.7 (26.0-40.5) 15.5 (3.3-NE)
Median PFS (95% CI), months 14.0 (11.2-14.9) 7.5 (3.6-16.6) 14.0 (11.1-16.2) 7.7 (1.9-16.6) 13.0 (10.3-15.4) 5.3 (1.6-NE)
Abbreviations: ETS ¼ early tumor shrinkage; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; NE ¼ not estimable; OS ¼ overall survival;
PFS ¼ progression-free survival; wt ¼ wild type.
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8 - Cli(IQR, 38.1-79.0), respectively. The median time to tumor size
nadir was 5.9 months (95% CI, 5.6-7.6) within the overall DpR-
evaluable population; median time to nadir was 5.9 months (95%
CI, 5.6-7.6) and 7.4 months (95% CI, 5.1-9.2) within theTable 4 AEs (‡5% Grade 3/4) in KRAS wt and RAS wt Populations
AE
KRAS wt (ITT), n (%)
Cetuximab D FOLFOX
(n [ 188)
Cetuximab D
(n [ 1
Any Grade Grade 3/4 Any Grade
Any 180 (95.7) 151 (80.3) 99 (98.0)
Neutropenia 101 (53.7) 73 (38.8) 56 (55.4)
Rash 115 (61.2) 29 (15.4) 55 (54.5)
Peripheral neuropathy 63 (33.5) 20 (10.6) 4 (4.0)
Diarrhea 81 (43.1) 16 (8.5) 59 (58.5)
Paronychia 49 (26.1) 14 (7.4) 33 (32.7)
Peripheral sensory neuropathy 34 (18.1) 12 (6.4) 1 (1.0)
Hypokalemia 33 (17.6) 11 (5.9) 23 (22.8)
Mucosal inﬂammation 54 (28.7) 11 (5.9) 15 (14.9)
Stomatitis 52 (27.7) 8 (4.3) 31 (30.7)
Palmareplantar
erythrodysesthesia syndrome
30 (16.0) 8 (4.3) 11 (10.9)
Fatigue 48 (25.5) 6 (3.2) 21 (20.8)
Hypophosphatemia 6 (3.2) 4 (2.1) 4 (4.0)
Dermatitis acneiform 21 (11.2) 3 (1.6) 12 (11.9)
Hyperglycemia 5 (2.7) 3 (1.6) 4 (4.0)
Leukopenia 28 (14.9) 3 (1.6) 24 (23.8)
Vomiting 65 (34.6) 3 (1.6) 38 (37.6)
Intestinal obstruction 2 (1.1) 2 (1.1) 6 (5.9)
Composite Categories
of Special Interest
Acnelike rash 150 (79.8) 35 (18.6) 76 (75.2)
Infusion-related reactions 23 (12.2) 9 (4.8) 1 (1.0)
Cardiac events 7 (3.7) 3 (1.6) 10 (9.9)
Septic events 4 (2.1) 4 (2.1) 4 (4.0)
Inclusion and sorting of AEs was based on grade 3/4 AEs that were observed in  5% of patients
Abbreviations: AE ¼ adverse event; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxa
nical Colorectal Cancer Month 2016FOLFOX and FOLFIRI treatment subgroups, respectively.
Notably, there appeared to be an association between the extent of
DpR and time to tumor size nadir: patients experiencing a deeper
response seemed to achieve maximal tumor shrinkage later thanRAS wt, n (%)
FOLFIRI
01)
Cetuximab D FOLFOX
(n [ 110)
Cetuximab D FOLFIRI
(n [ 57)
Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4
75 (74.3) 108 (98.2) 91 (82.7) 57 (100) 47 (82.5)
36 (35.6) 64 (58.2) 47 (42.7) 35 (61.4) 22 (38.6)
4 (4.0) 70 (63.6) 16 (14.5) 38 (66.7) 4 (7.0)
0 43 (39.1) 12 (10.9) 3 (5.3) 0
12 (11.9) 46 (41.8) 9 (8.2) 35 (61.4) 9 (15.8)
10 (9.9) 32 (29.1) 11 (10.0) 18 (31.6) 7 (12.3)
0 19 (17.3) 7 (6.4) 1 (1.8) 0
11 (10.9) 21 (19.1) 8 (7.3) 17 (29.8) 9 (15.8)
2 (2.0) 36 (32.7) 5 (4.5) 7 (12.3) 1 (1.8)
9 (8.9) 33 (30.0) 4 (3.6) 20 (35.1) 6 (10.5)
2 (2.0) 16 (14.5) 6 (5.5) 7 (12.3) 2 (3.5)
4 (4.0) 33 (30.0) 5 (4.5) 15 (26.3) 3 (5.3)
3 (3.0) 3 (2.7) 2 (1.8) 4 (7.0) 3 (5.3)
5 (5.0) 16 (14.5) 2 (1.8) 6 (10.5) 4 (7.0)
3 (3.0) 4 (3.6) 2 (1.8) 4 (7.0) 3 (5.3)
6 (5.9) 18 (16.4) 1 (0.9) 17 (29.8) 6 (10.5)
5 (5.0) 33 (30.0) 2 (1.8) 25 (43.9) 3 (5.3)
4 (4.0) 1 (0.9) 1 (0.9) 5 (8.8) 4 (7.0)
11 (10.9) 91 (82.7) 18 (16.4) 46 (80.7) 10 (17.5)
0 12 (10.9) 5 (4.5) 1 (1.8) 0
3 (3.0) 5 (4.5) 2 (1.8) 9 (15.8) 3 (5.3)
4 (4.0) 3 (2.7) 3 (2.7) 3 (5.3) 3 (5.3)
in either treatment subgroup in either population.
liplatin/folinic acid/5-ﬂuorouracil; ITT ¼ intention-to-treat; wt ¼ wild type.
Ann-Lii Cheng et alpatients with a less deep response (Supplemental Figure 2; avail-
able in the online version). Furthermore, the data suggest that
there was a relationship between the extent of DpR and PFS/OS
(Supplemental Figure 3; available in the online version).
Safety
Neutropenia was the most common grade 3/4 AE in both
treatment subgroups of the KRAS wt population. Grade 3/4
infusion-related reactions occurred in 4.8% of patients receiving
cetuximab plus FOLFOX and in none of those receiving cetuximab
plus FOLFIRI. Grade 3/4 acne-like rash occurred in 18.6% and
10.9% of patients receiving cetuximab in combination with FOL-
FOX and FOLFIRI, respectively (Table 4).
Serious AEs (SAEs) were experienced by 34.0% of patients
treated with FOLFOX plus cetuximab and 36.6% of patients
receiving FOLFIRI plus cetuximab in the KRAS wt population;
pyrexia (3.7%) was the most common SAE among patients in the
FOLFOX treatment subgroup, whereas intestinal obstruction
(5.0%) was the most frequent SAE in the FOLFIRI treatment
subgroup; the only other SAEs that occurred with  3% incidence
in either treatment subgroup of the KRAS wt population were
febrile neutropenia and diarrhea in the FOLFOX subgroup and
neutropenia, diarrhea, pyrexia, hypokalemia, and deep vein
thrombosis in the FOLFIRI subgroup. Within the KRAS wt pop-
ulation, 11.7% and 16.8% of patients in the FOLFOX and
FOLFIRI subgroups experienced AEs leading to the permanent
discontinuation of cetuximab, respectively. Skin and subcutaneous
tissue disorders were responsible for permanent discontinuation of
cetuximab in 2.7% and 3.0% of patients in the FOLFOX and
FOLFIRI treatment subgroups, respectively. Oxaliplatin was
permanently discontinued before conﬁrmation of progressive disease
in 33.5% of patients receiving FOLFOX, while irinotecan was
permanently discontinued in 15.8% of patients receiving FOLFIRI.
There were 4 deaths reported in the study; 2 of them were cate-
gorized as due to disease complication with no evidence of pro-
gression, the third one (interstitial pneumonitis) as being reasonably
related to cetuximab plus FOLFOX combination as assessed by the
investigator, and the last one as treatment related due to unex-
plained death with missing relationship.
The safety proﬁle of cetuximab plus chemotherapy in both RAS
wt treatment subgroups was comparable with that described above
for the KRAS wt population. No new safety ﬁndings were identiﬁed
(Table 4).
Discussion
The APEC study has shown that once-every-2-weeks cetuximab
with either FOLFOX or FOLFIRI is effective as a ﬁrst-line therapy
for mCRC in this Asia-Paciﬁc study population. The observed
median OS for the KRAS wt and RAS wt populations is similar to
those reported in prior ﬁrst-line pivotal studies involving weekly
cetuximab plus FOLFOX or FOLFIRI that enrolled mainly white
patients.2,5,14-16
Cetuximab compliance in the APEC study was high, and the
overall occurrence of AEs, including grade 3/4 acneiform skin re-
actions, was similar to historical rates for the weekly administration
schedule of cetuximab plus chemotherapy and chemotherapy
alone.2,5Notably, the CECOG CORE 1.2.002 study has shown that the
efﬁcacy and safety of cetuximab in combination with FOLFOX4 is
similar when administered weekly versus once every 2 weeks in
patients with KRAS wt mCRC.7,14 These observations are further
substantiated by data from the OPTIMIX and NORDIC 7.5
studies demonstrating the efﬁcacy and tolerability of a once-every-2-
weeks cetuximab regimen.8,9 Accordingly, once-every-2-weeks
cetuximab may represent an alternative to weekly administration.
Although this was not a randomized study and no formal sta-
tistical hypotheses were planned to be evaluated between treatment
subgroups, as expected, the data suggest that cetuximab can be
effectively combined with either chemotherapy regimen (FOLFOX
or FOLFIRI). These ﬁndings are consistent with the CRYSTAL,
OPUS, FIRE-3, and CALGB 80405 trials.2,5,15-17 Furthermore, the
safety proﬁle within both treatment subgroups of the KRAS wt and
RAS wt populations was comparable, and no new safety ﬁndings
were identiﬁed.
Rates of mutation in RAS (KRAS/NRAS exons 2-4), BRAF, and
PIK3CA were consistent with those of previous studies,2,5,18 sug-
gesting that the mutation frequencies of these genes appear to be
similar between Asians and whites. In accordance with our expec-
tations, BORR, median PFS, and median OS were relatively low in
patients with RAS mt mCRC, as compared with patients with RAS
wt mCRC. Furthermore, relative to the KRAS wt population, the
efﬁcacy of cetuximab was numerically improved in the RAS wt
population, demonstrating that expanded testing of RAS mutational
status reveals a population of patients with better clinical outcomes.
These results underline the importance of expanded RAS testing to
select patients most likely to beneﬁt from therapy with cetuximab.
A prognostic role for BRAF and PIK3CA in mCRC has been
suggested previously, although the potential predictive value of these
2 biomarkers remains controversial.19,20 In our study, there
appeared to be a trend toward improved outcomes in the BRAF/
PIK3CA wt population compared with the mt populations; how-
ever, further studies with larger numbers of patients with BRAF/
PIK3CA mt tumors are needed to provide a conclusive result.
Prior studies have indicated that patients with EGFR-
undetectable mCRC can respond to cetuximab.21,22 Although the
relatively small number of patients in certain subgroups is a limi-
tation of the present study, our results appear to be broadly
consistent with these previous observations.
Although the number of patients in certain subgroups of our
study was relatively small, our results suggest that patients with ETS
or high DpR may have derived increased beneﬁt, in terms of PFS
and OS, from cetuximab plus chemotherapy. These ﬁndings are
similar to earlier subgroup analyses of analogous pivotal studies
involving weekly cetuximab, as ETS has been correlated with
improved long-term outcome in patients with KRAS/RAS wt mCRC
treated with weekly cetuximab in the CRYSTAL and OPUS (at 8
weeks) as well as the FIRE-3 (at 6 weeks) trials23,24; similarly, extent
of DpR has been associated with survival outcomes in CRYSTAL,
OPUS, and FIRE-3.24,25
Our data further suggest that there are patients with RAS wt
mCRC who may beneﬁt from the continuation of treatment with
cetuximab plus FOLFOX or FOLFIRI rather than treatment breaks
(eg, upon ETS) to achieve maximal tumor reduction. Indeed, in our
study, the median duration of cetuximab treatment was relativelyClinical Colorectal Cancer Month 2016 - 9
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10 -long (z7.5 months) and exceeded the median duration of
chemotherapy administration (especially in the subgroup treated
with FOLFOX and less pronounced in the FOLFIRI subgroup;
Supplemental Table 3; available in the online version). The rela-
tively long median PFS observed here (11.1 months in the KRAS wt
population) is therefore noteworthy and consistent with the results
of COIN-B,26 suggesting that patients may derive beneﬁt from the
use of cetuximab as a maintenance regimen.
Conclusion
The present observations suggest that cetuximab plus FOLFOX
or FOLFIRI in a once-every-2-week regimen is effective and
tolerable as ﬁrst-line therapy in this Asia-Paciﬁc study population.
Thus, once-every-2-weeks cetuximab may represent an alternative
to weekly administration in patients with KRAS wt or RAS wt
mCRC.
Clinical Practice Points
 A chemotherapy doublet (either FOLFOX or FOLFIRI) plus
weekly cetuximab represents standard-of-care ﬁrst-line therapy
for patients with KRAS/RAS wt mCRC. Indeed, the safety and
efﬁcacy of such a weekly regimen in patients with KRAS/RAS wt
mCRC has been ﬁrmly established by the pivotal ﬁrst-line
CRYSTAL and OPUS studies.
 The present nonrandomized phase 2 trial investigated whether
the well-tolerated beneﬁcial treatment effect observed in patients
with KRAS/RAS wt mCRC on adding weekly cetuximab to ﬁrst-
line chemotherapy persisted when the regimen was administered
according to a once-every-2-weeks dosing schedule.
 Our ﬁndings suggest an activity and safety proﬁle for 500 mg/m2
cetuximab once every 2 weeks plus chemotherapy is similar to
that reported in prior ﬁrst-line pivotal studies involving weekly
administration of 250 mg/m2 after an initial dose of 400 mg/m2.
 Accordingly—consistent with observations from the CECOG
CORE1.2.002,NORDIC7.5, andOPTIMIX trials—the impact
of the present study on future clinical practice is empirical vali-
dation of the effectiveness and tolerability of once-every-2-weeks
cetuximab plus ﬁrst-line chemotherapy in patients with KRAS/
RAS wt mCRC, suggesting that a once-every-2-weeks dosing
schedule may represent an alternative to weekly administration.
 Our study further establishes that cetuximab can be effectively
combined with either FOLFOX or FOLFIRI, a ﬁnding that is
supported by data from the CRYSTAL, OPUS, FIRE-3, and
CALGB 80405 trials.Acknowledgments
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Supplemental Figure 1 Extent of Tumor Shrinkage in Nonprogresssing Patients Within RAS wt Population
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Supplemental Figure 2 Association Between Extent of DpR and Time to Tumor Size Nadir in RAS wt Population
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Abbreviations: DpR ¼ depth of response; wt ¼ wild type.
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Supplemental Figure 3 Relationship Between Extent of DpR and PFS (A) and OS (B) in RAS wt Population. Crosshairs Denote Median
DpR (%) and PFS/OS Time (Months)
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Abbreviations: DpR¼ depth of response; FOLFIRI¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; OS ¼ overall survival; PFS ¼ progression-free survival; wt ¼
wild type.
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Supplemental Table 1 Rate of Biomarker Mutation Detection
Mutation
Total
(n [ 289)a,b
Cetuximab D
FOLFOX
(n [ 188)a,b
Cetuximab D
FOLFIRI
(n [ 101)
KRAS, n (%)
Exon 2 10 (3.5) 6 (3.2) 4 (4.0)
Exon 3 6 (2.1) 4 (2.1) 2 (2.0)
Exon 4 7 (2.4) 4 (2.1) 3 (3.0)
NRAS, n (%)
Exon 2 5 (1.7) 4 (2.1) 1 (1.0)
Exon 3 9 (3.1) 7 (3.7) 2 (2.0)
Exon 4 0 0 0
BRAF, n (%) 16 (5.5) 10 (5.3) 6 (5.9)
PIK3CA, n (%)
Exon 9 10 (3.5) 7 (3.7) 3 (3.0)
Exon 20 3 (1.0) 2 (1.1) 1 (1.0)
BRAF mt and/or
PIK3CA mt, n (%)
29 (10.0) 19 (10.1) 10 (10.0)
EGFR, n
Evaluable 154 100 54
Detectable 124 81 43
Undetectable 30 19 11
Abbreviations: EGFR ¼ epidermal growth factor receptor; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/
irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; mt ¼ mutant; wt ¼ wild type.
aOne patient had 2 RAS mutations; the total number of patients with RAS mt mCRC was 36.
bOne patient had 2 BRAF and/or PIK3CA mutations; the total number of patients with BRAF mt
and/or PIK3CA mt mCRC was 28.
Supplemental Table 2 Treatment Exposure in KRAS wt
Population
Relative Dose
Intensity
Cetuximab D
FOLFOX
(n [ 188), n (%)
Cetuximab D
FOLFIRI
(n [ 101), n (%)
Cetuximab
<60% 6 (3.2) 2 (2.0)
60%-80% 36 (19.1) 24 (23.8)
80%-90% 33 (17.6) 21 (20.8)
90% 113 (60.1) 54 (53.5)
Irinotecan
<60% 12 (11.9)
60%-80% — 41 (40.6)
80%-90% 19 (18.8)
90% 29 (28.7)
Oxaliplatin
<60% 21 (11.2)
60%-80% 76 (40.4) —
80%-90% 33 (17.6)
90% 58 (30.9)
5-FU
<60% 28 (14.9) 15 (14.9)
60%-80% 79 (42.0) 38 (37.6)
80%-90% 27 (14.4) 18 (17.8)
90% 54 (28.7) 30 (29.7)
Abbreviations: 5-FU ¼ 5-ﬂuorouracil; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan;
FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; wt ¼ wild type.
Supplemental Table 3 Duration of Treatment (Weeks) in
KRAS wt Population
Therapy
Cetuximab D FOLFOX
(n [ 188)
Cetuximab D FOLFIRI
(n [ 101)
Cetuximab
Median 32.1 33.3
Q1-Q3 16.1-50.9 16.4-52.0
Irinotecan
Median — 32.0
Q1-Q3 16.1-47.1
Oxaliplatin
Median 25.4 —
Q1-Q3 15.9-31.9
5-FU
Median 27.8 32.0
Q1-Q3 16.9-41.6 16.1-46.1
Abbreviations: 5-FU ¼ 5-ﬂuorouracil; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan;
FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; wt ¼ wild type.
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Supplemental Table 4 PosteFirst-Line Treatments Received in KRAS wt Population
Therapy
Total (n [ 289),
n (%)
Cetuximab D FOLFOX
(n [ 188), n (%)
Cetuximab D FOLFIRI
(n [ 101), n (%)
Any Anticancer Therapy 171 (59.2) 110 (58.5) 61 (60.4)
PosteFirst-Line Therapy
Radiotherapy 37 (12.8) 19 (10.1) 18 (17.8)
Chemotherapy 151 (52.2) 103 (54.8) 48 (47.5)
Surgery 33 (11.4) 17 (9.0) 16 (15.8)
Othera 60 (20.8) 37 (19.7) 23 (22.8)
No. of Further Lines of Therapy
2 142 (49.1) 89 (47.3) 53 (52.5)
>2 29 (10.0) 21 (11.2) 8 (7.9)
Combination Therapy 131 (45.3) 87 (46.3) 44 (43.6)
Chemotherapy þ radiotherapy 4 (1.4) 1 (0.5) 3 (3.0)
Chemotherapy þ surgery þ othera 2 (0.7) 2 (1.1) 0
Chemotherapy þ other 44 (15.2) 30 (16.0) 14 (13.9)
Chemotherapy combination only 113 (39.1) 72 (38.3) 41 (40.6)
Abbreviations: FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; wt ¼ wild type.
aIncludes biologics cetuximab, bevacizumab, regorafenib, panitumumab, and INC280 (clinical trial drug).
Supplemental Table 5 Efﬁcacy in BRAF/PIK3CA-Evaluable Subpopulations
Therapy Evaluable
BRAF wt,
PIK3CA wt
BRAF and/or
PIK3CA mt
BRAF wt,
PIK3CA mt
BRAF mt,
PIK3CA wt
BRAF mt,
PIK3CA mt
Total
n 203 175 28 12 15 1
BORR (95% CI), % 59.1 (52.0-65.9) 61.1 (53.5-68.4) 46.4 (27.5-66.1) 58.3 (27.7-84.8) 33.3 (11.8-61.6) 100.0 (2.5-100.0)
PFS (95% CI), months 11.1 (9.2-13.5) 11.5 (10.3-14.6) 7.4 (5.5-7.8) 7.5 (5.6-13.5) 6.4 (3.7-7.8) 5.5 (NE)
OS (95% CI), months 26.7 (23.3-30.1) 28.7 (26.2-32.8) 13.8 (8.6-17.9) 17.7 (12.8-26.0) 9.0 (4.6-17.9) 8.6 (NE)
Cetuximab D FOLFOX
n 134 116 18 8 9 1
BORR (95% CI), % 59.0 (50.1-67.4) 61.2 (51.7-70.1) 44.4 (21.5-69.2) 75.0 (34.9-96.8) 11.1 (0.3-48.2) 100.0 (2.5-100.0)
PFS (95% CI), months 11.0 (8.3-13.6) 11.5 (9.3-14.9) 7.4 (3.7-7.8) 8.3 (2.6-13.5) 4.6 (1.6-7.7) 5.5 (NE)
OS (95% CI), months 26.7 (22.2-30.3) 28.5 (23.4-33.2) 11.1 (4.6-17.7) 17.7 (2.6-25.7) 6.9 (2.8-11.1) 8.6 (NE)
Cetuximab D FOLFIRI
n 69 59 10 4 6 0
BORR (95% CI), % 59.4 (46.9-71.1) 61.0 (47.4-73.5) 50.0 (18.7-81.3) 25.0 (0.6-80.6) 66.7 (22.3-95.7) NE
PFS (95% CI), months 11.4 (8.1-14.9) 11.4 (9.3-15.4) 7.3 (5.3-14.8) 5.9 (5.6-.) 11.0 (5.3-.) NE
OS (95% CI), months 26.6 (21.5-33.8) 28.7 (23.5-37.3) 18.2 (8.8-26.0) 20.5 (12.8-42.8) 18.2 (8.8-.) NE
Abbreviations: BORR ¼ best conﬁrmed overall response rate; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/5-ﬂuorouracil; mt ¼ mutant; NE ¼ not estimable;
OS ¼ overall survival; PFS ¼ progression-free survival; wt ¼ wild type.
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Supplemental Table 6 Efﬁcacy in EGFR-Evaluable Subpopulations
Therapy Evaluable EGFR Detectable EGFR Undetectable
Total
n 154 124 30
BORR (95% CI), % 53.9 (45.7-62.0) 56.5 (47.3-65.3) 43.3 (25.5-62.6)
PFS (95% CI), months 11.1 (8.3-13.6) 11.1 (8.1-14.1) 11.1 (5.5-22.1)
OS (95% CI), months 28.4 (24.4-33.8) 28.7 (23.7-34.6) 27.8 (18.2-37.7)
Cetuximab D FOLFOX
n 100 81 19
BORR (95% CI), % 56.0 (45.7-65.9) 58.0 (46.5-68.9) 47.4 (24.4-71.1)
PFS (95% CI), months 11.1 (7.7-14.2) 11.1 (7.5-14.2) 11.1 (7.7-23.0)
OS (95% CI), months 28.5 (23.7-34.2) 31.3 (23.7-35.2) 27.8 (16.9-31.8)
Cetuximab D FOLFIRI
n 54 43 11
BORR (95% CI), % 50.0 (36.1-63.9) 53.5 (37.7-68.8) 36.4 (10.9-69.2)
PFS (95% CI), months 11.1 (7.4-16.6) 11.0 (7.4-16.6) 22.1 (2.4-27.7)
OS (95% CI), months 26.8 (17.2-40.5) 26.8 (16.6-37.3) 26.2 (5.3-NE)
Abbreviations: BORR ¼ best conﬁrmed overall response rate; EGFR ¼ epidermal growth factor receptor; FOLFIRI ¼ 5-ﬂuorouracil/folinic acid/irinotecan; FOLFOX ¼ oxaliplatin/folinic acid/
5-ﬂuorouracil; NE ¼ not estimable; OS ¼ overall survival; PFS ¼ progression-free survival.
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